UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 1, 2007
Pain Therapeutics
(Exact name of registrant as specified in its charter)
|
Delaware |
000-29959 |
91-1911336 |
||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
2211 Bridgepointe Parkway, Suite 500, San Mateo, CA |
94404 |
|||
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (650) 624-8200
________________________________________________________________________________
(Former name or former address, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 2.02. Results of Operations and Financial Condition.
On November 1, 2007 Pain Therapeutics, Inc. (the "Company") issued a press release announcing the Company's financial results for the three and nine months ended September 30, 2007. A copy of the press release has been furnished as an exhibit to this report and is incorporated by reference herein.
The information in this Current Report on Form 8-K and in Exhibit 99.1 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference into any registration statement or other document filed or furnished pursuant to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
The following exhibit is furnished as part of this Current Report on Form 8-K.
Exhibit
Number
Description
99.1
Press Release of Pain Therapeutics, Inc. dated November 1, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Pain Therapeutics
(Registrant) |
||
|
November 1, 2007
(Date) |
/s/ PETER S. RODDY
Peter S. Roddy VP & Chief Financial Officer |
| Exhibit Index | ||
| 99.1 | Press release dated November 1, 2007 | |
EXHIBIT 99.1
Pain Therapeutics Announces Third Quarter 2007 Financial Results
Company On-track to Release Remoxy Phase III Results in Q4
SAN MATEO, Calif., Nov. 1, 2007 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the three and nine months ended September 30, 2007. Net income for the quarter ended September 30, 2007 was $3.2 million, or $0.07 per diluted share, compared to $9.7 million, or $0.21 per diluted share, in the third quarter of 2006. Net income for the nine months ended September 30, 2007 was $19.2 million, or $0.42 per diluted share, compared to $11.9 million, or $0.26 per diluted share, for the same period in 2006.
Cash, cash equivalents and marketable securities were $205.9 million at September 30, 2007. Pain Therapeutics now expects its 2007 net cash requirements to be $5.0 million or less, plus any amounts related to a previously announced stock buyback plan of up to $20.0 million. As of September 30, 2007 we had purchased $3.8 million of our common stock on the open market.
"We think our financial performance continues to create fertile grounds for success," said Remi Barbier, Pain Therapeutics' president and chief executive officer. "In Q4 2007, we plan to release top-line results of our Phase III pivotal study for Remoxy, our abuse-deterrent opioid painkiller. For now, the Remoxy study remains blinded while the last patients' data are being gathered."
Financial Highlights
* We have a collaboration with King Pharmaceuticals, Inc. ("King") to
develop Remoxy and other abuse-deterrent opioid painkillers. King
gave us an upfront cash payment of $150.0 million in December 2005.
For accounting purposes, we plan to recognize a portion of this cash
payment as "program fee revenue" each quarter through July 2011. We
recognized program fee revenue of $6.6 million this quarter.
* Collaboration revenues were $9.3 million and $32.3 million in the
three and nine months ended September 30, 2007, respectively and
$7.0 million and $22.9 million in the three and nine months ended
September 30, 2006, respectively.
* Research and development expenses for the third quarter of 2007
increased to $13.3 million from $10.5 million for the third quarter
of 2006. Research and development expenses for the nine months
ended September 30, 2007 increased to $34.2 million from $33.5
million for the same period in 2006. Research and development
expenses included non-cash stock related compensation costs of $1.0
million in the three months ended September 30, 2007 and 2006 and
$2.5 million and $2.8 million in the nine months ended September 30,
2007 and 2006, respectively.
* General and administrative expenses increased to $2.0 million from
$1.7 million in the three months ended September 30, 2007 and 2006,
respectively, and increased to $6.0 million from $5.7 million in
the nine months ended September 30, 2007 and 2006, respectively.
General and administrative expenses included non-cash stock related
compensation costs of $0.6 million and $0.7 million in the three
months ended September 30, 2007 and 2006, respectively, and $1.7
million and $2.0 million in the nine months ended September 30,
2007 and 2006, respectively.
* On March 29, 2007, we announced a stock buyback plan of up to $20.0
million of our common stock. As of September 30, 2007 we had
purchased $3.8 million of our common stock on the open market.
The total number of shares to be purchased and the timing of
purchases will be based on several factors, including the price of
the common stock, general market conditions, corporate and
regulatory requirements and alternate investment opportunities.
We intend to hold repurchased shares in treasury. This stock
buyback program expires March 2008 and may be modified or
discontinued at any time.
* We have not provided for income taxes for the third quarter of 2007
because we do not expect to have taxable income for the full year
2007. Our income before income taxes in 2007 includes program fee
revenue. For tax purposes, we recognized all of the related program
fee revenue in 2006, which is the primary reason for our
expectations for no taxable income for 2007.
About Pain Therapeutics, Inc.
Pain Therapeutics is a biopharmaceutical company that develops novel drugs. We have four investigational drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. We are also working on a new treatment for patients with hemophilia. The FDA has not yet evaluated the merits, safety or efficacy of our drug candidates. For more information, please visit www.paintrials.com.
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates including the timing of the Company's Phase III announcement with Remoxy, the potential benefits of the Company's drug candidates, the time period for program fee revenue recognition, and the Company's expected cash requirements in 2007. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks an d uncertainties relating to difficulties or delays in development and testing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the uncertainty of patent protection for the Company's intellectual property or trade secrets and unanticipated research and development and other costs. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.
PAIN THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- --------------------
2007 2006 2007 2006
--------- --------- --------- ---------
Revenue
Program fee revenue $ 6,551 $ 6,550 $ 19,651 $ 19,651
Collaboration revenue 9,259 6,960 32,277 22,931
Milestone revenue -- 5,000 -- 5,000
--------- --------- --------- ---------
Total revenue 15,810 18,510 51,928 47,582
Operating expenses
Research and development 13,268 10,471 34,171 33,513
General and
administrative 2,011 1,686 5,951 5,706
--------- --------- --------- ---------
Total operating
expenses 15,279 12,157 40,122 39,219
--------- --------- --------- ---------
Operating income 531 6,353 11,806 8,363
Interest and other
income, net 2,642 2,559 7,368 7,115
--------- --------- --------- ---------
Income before provision
for (benefit from)
income taxes 3,173 8,912 19,174 15,478
Provision for (benefit
from) income taxes -- (744) -- 3,579
--------- --------- --------- ---------
Net income $ 3,173 $ 9,656 $ 19,174 $ 11,899
========= ========= ========= =========
Net income per share
Basic $ 0.07 $ 0.22 $ 0.43 $ 0.27
========= ========= ========= =========
Diluted $ 0.07 $ 0.21 $ 0.42 $ 0.26
========= ========= ========= =========
Weighted-average shares
used in computing
net income per share
Basic 44,049 44,184 44,138 44,106
========= ========= ========= =========
Diluted 45,655 45,221 45,413 45,323
========= ========= ========= =========
PAIN THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
September 30, December 31,
2007 2006 (1)
------------ ------------
(Unaudited)
Assets
Current assets
Cash, cash equivalents and
marketable securities $ 205,927 $ 204,400
Other current assets 480 2,714
------------ ------------
Total current assets 206,407 207,114
Non-current assets
Property and equipment, net 1,549 1,267
Other assets 854 75
------------ ------------
Total assets $ 208,810 $ 208,456
============ ============
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 3,008 $ 985
Accrued development expense 3,916 5,777
Deferred program fee revenue -
current portion 26,200 26,200
Income taxes payable -- 2,779
Other accrued liabilities 1,638 913
------------ ------------
Total current liabilities 34,762 36,654
Non-current liabilities
Deferred program fee revenue -
non-current portion 74,237 93,887
Other liabilities 763 --
------------ ------------
Total liabilities 109,762 130,541
------------ ------------
Stockholders' equity
Common stock 44 44
Additional paid-in-capital 217,910 214,749
Accumulative other comprehensive
income (loss) 354 (372)
Accumulated deficit (119,260) (136,506)
------------ ------------
Total stockholders' equity 99,048 77,915
------------ ------------
Total liabilities and
stockholders' equity $ 208,810 $ 208,456
============ ============
(1) Derived from audited financial statements.
CONTACT: Pain Therapeutics, Inc.
Christi Waarich, Senior Manager of Investor Relations
650-645-1924
cwaarich@paintrials.com